Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3 -mutated ( FLT3 mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Year: 2019
Type: conference-abstract
Source: Cancer Research
Authors: Alexander E. Perl, Giovanni Martinelli, Jorge E. Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, Maria R. Baer, Richard A. Larson, Celalettin Ustun, Francesco Fabbiano, Antonio Di Stasi, Robert Stuart, Rebecca Olin, Margaret Kasner, Fabio Ciceri, Wen-Chien Chou, Nikolai Podoltsev, Christian Recher, Hisayuki Yokoyama, Naoko Hosono, Sung-Soo Yoon, Je-Hwan Lee, Timothy Pardee, Amir T. Fathi, Chaofeng Liu, Xuan Liu, Erkut Bahceci, Mark J. Levis
Institutions: Abramson Cancer Center, University of Pennsylvania, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, The University of Texas MD Anderson Cancer Center, Universitätsklinikum Gießen und Marburg, Memorial Sloan Kettering Cancer Center, University of Bologna, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cáncer, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, University of Minnesota, Ospedale Vincenzo Cervello, University of Alabama at Birmingham, Medical University of South Carolina, MUSC Hollings Cancer Center, University of California, San Francisco, Thomas Jefferson University, National Taiwan University, Yale University, Institut universitaire du cancer de Toulouse Oncopole, Sendai Medical Center, National Hospital Organization, University of Fukui, Seoul National University, Asan Medical Center, University of Ulsan, Atrium Health Wake Forest Baptist, Harvard University, Massachusetts General Hospital, Astellas Pharma (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2955239052